Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Philippe Gabríel Steg et al.|New England Journal of Medicine|2018Cited by 3.5k
Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>Lawrence A. Leiter, Yehuda Handelsman, Guillaume Lecorps et al.|Diabetes Obesity and Metabolism|2017Cited by 50